BCR signaling and OXPHOS are directly linked in CLL, as evidenced by genetic ablation studies knocking out PI3Kδ (49), as well as by our findings with iBTK treatment in patients showing that regression of metabolic activity from an energetic to a quiescent state associates with the level of disease activity. This evidence concerns the gene IBTK and B-cell chronic lymphocytic leukemia.